Document:

EX-10.13

 Exhibit 10.13 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS
EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 
 REDEEMABLE
PREFERRED STOCK REDEMPTION AGREEMENT 
 THIS REDEEMABLE PREFERRED STOCK REDEMPTION AGREEMENT (this “Agreement”)
is made and entered into effective as of September 17, 2018 by and between VIRACYTE, INC., a Delaware corporation (the “Company”), and the undersigned individuals (individually each a “Shareholder” and
collectively “Shareholders”). 
 WHEREAS, Exhibit A attached hereto lists all Series A1 Preferred Stock and
Redeemable Preferred Stock in the Company owned by the Shareholders (collectively, the “Shares”). 
 WHEREAS,
certain of the Shareholders (each a “Seller” and collectively “Sellers”) are selling certain of their respective Shares to the Company as shown on Exhibit A (the “Redeemed Shares”), subject to the
terms and conditions of this Agreement. 
 WHEREAS, the Shareholders and the Company desire to induce a purchaser to purchase shares
of Series A2 Preferred Stock of the Company, par value $0.0001 per share (“Series A2 Preferred Stock”), pursuant to that certain Series A2 Preferred Stock Purchase Agreement dated as of the date hereof by and among the Company, the
Shareholders and such purchaser (the “Purchase Agreement”) by entering into this Agreement. 
 NOW, THEREFORE, in
consideration of the premises, the mutual agreements set forth below, inducement of the purchase of Series A2 Preferred Stock by the purchaser pursuant to the Purchase Agreement and other good and valuable consideration, the receipt and adequacy of
which is hereby acknowledged, the parties agree as follows: 
 ARTICLE 1. 

PURCHASE AND SALE OF THE SHARES 

1.1. Purchase and Sale. On the terms and conditions contained in this Agreement, on the “Closing Date” (as such
term is defined herein), Sellers shall sell and assign the Redeemed Shares to the Company, and the Company shall purchase the Redeemed Shares from Sellers. 

ARTICLE 2. 
 PURCHASE
PRICE AND TERMS 
 2.1. Purchase Price. The aggregate purchase price for the Redeemed Shares shall be as follows
(the “Purchase Price”): 
 (a) [***] (the “Closing Payment”), plus 

(b) The Earnout Payments described herein. 

2.2. Payment Terms. On the Closing Date, the Company shall pay the Closing Payment to Sellers prorata in accordance with
their respective Redemption Price as shown on Exhibit A, by wire transfer of certified funds in exchange for such Seller’s Redeemed Shares. 

For clarity, no payments shall be owed under this Section 2.2 or Section 2.3 to Shareholders that are not Sellers. 

 2.3 Earnout Payments. During the Earnout Period (as defined below), on at
least an annual basis, on such date as determined by the Board of Directors of the Company provided that such date shall be within 120 days of the end of each calendar quarter (each a “Quarterly Period”), the Company shall make an
Earnout Payment to the Sellers on a prorata basis in accordance with the percentages shown in Exhibit A in the column “Earnout Payment Percentages” (“Prorata Percentages”) shown on Exhibit A. 

(a) “Earnout Payment” means an aggregate amount equal to the Earnout Percentage Product (as defined in
Section 2.3(c) below) multiplied by the Company’s Net Sales (as defined in Section 2.3(d) below) of Viralym-M less the Company’s then existing third party royalty obligations from the sale of Viralym-M Product, including without
limitation (i) any payments owed under that certain Exclusive License Agreement between Company (as successor to Viracyte LLC) and Baylor College of Medicine, effective as of June 30, 2017 (as amended from time to time) and (ii) any
payments owed under that certain Cancer Research Grant Contract between Company (as successor to Viracyte LLC) and the Cancer Prevention and Research Institute of Texas (as amended from time to time), in each case ((i) or (ii)) with respect to sales
of Viralym-M Product. 
 (b) “Earnout Period” means a period of [***] years from the date of the first commercial
sale of Viralym-M Product by the Company. 
 (c) “Earnout Percentage” means 10%; provided that, the foregoing shall
be reduced from [***] to [***] if, during the three year period after the first commercial sale of Viralym-M Product by the Company, the Company pays Sellers, in accordance with their respective Prorata Percentages shown on Exhibit A, an aggregate
amount of at least [***]. 
 (d) “Net Sales” means on a
country-by-country and Viralym-M Product-by-Viralym- M Product basis, with respect to the applicable payment Quarterly Period for
each country, the gross amounts invoiced by the Company or its sublicensees, (each, a “Selling Party”) to unrelated third parties for sales of a Viralym-M Product in such country, less the following deductions to the extent included
in the gross invoiced sales price for such Viralym-M Product or otherwise paid, incurred, allowed, accrued or specifically allocated by the Selling Parties with respect to the sale of such Viralym-M Product in such country: 

(i) discounts, including customary trade, quantity or cash discounts, credits adjustments or allowances, including those granted on account of
price adjustments, billing errors, rejected goods, or damaged goods; 
 (ii) rebates and chargebacks allowed, given or accrued (including
cash, governmental and managed care rebates, hospital or other buying group chargebacks, cash and non-cash coupons, retroactive price reductions, and governmental taxes in the nature of a rebate based on usage
levels or sales of such Viralym-M Product); 

  
 2 

 (iii) uncollectible amounts and charge-offs for bad debts in respect of sales of such
Viralym-M Product; 
 (iv) sales, excise, turnover, inventory, value-added, import, export, excise (including annual fees due under
Section 9008 of the United States Patient Protection and Affordable Care Action of 2010 (Pub. L. No. 111-48) and other comparable laws) and other taxes levied on, absorbed, determined or imposed with
respect to the sale of such Viralym-M Product (excluding income or net profit taxes or franchise taxes of any kind); and 
 (v) reasonable
charges for delivery or transportation of Viralym-M Product to customers through the use of third party delivery or transportation services, if separately stated. 

Net Sales will be determined in accordance with GAAP. Without limiting the generality of the foregoing, transfers or dispositions of a
Viralym-M Product for charitable, promotional (including samples), pre-clinical, clinical, or regulatory purposes will be excluded from Net Sales, as will sales or transfers of a Viralym-M Product among the
Selling Parties. 
 Subject to the above deductions, Net Sales shall be deemed to occur on, and only on, the first sale by a Selling Party to
a non-sublicensee third party. If non-monetary consideration is received by a Selling Party for the Viralym-M Product in the relevant country, Net Sales will be calculated based on the average price charged
for such Viralym-M Product, as applicable, during the preceding Quarterly Period, or in the absence of such sales, the fair market value of the Viralym-M Product, as applicable, as determined by the Board of Directors of the Company in good faith.

 (e) “Viralym-M Product” means a non-genetically engineered T-cell product composed of virus-specific T cells that have native T cell receptors that recognize virus infected cells that present antigens from one or more of the following: (i) cytomegalovirus (CMV), (ii)
adenovirus (AdV), (iii) Epstein-Barr virus (EBV), (iv) Human herpesvirus-6 (HHV6), (v) BK virus (BK), (vi) JC virus, and (vii) Merkel cell polyomavirus. Viralym-M shall not include any products that are
part of the Company’s respiratory VST program. 
 ARTICLE 3. 

CLOSING 
 3.1.
Closing. The Closing of the purchase and sale of the Redeemed Shares shall take place within 10 days after the closing of the Financing (as defined below) at such time and location as determined by the Company (the “Closing
Date”). The effective time of the Closing shall be as of 11:59 p.m. on the Closing Date. 

  
 3 

 ARTICLE 4. 

REPRESENTATIONS, WARRANTIES AND ACKNOWLEDGEMENTS OF EACH 

SELLER 
 In connection with
and as an inducement to the Company to enter into this Agreement, each Seller represents and warrants to the Company that, as of the Closing Date: 

4.1. No Conflicts. The execution and delivery of this Agreement does not, and the performance by such Seller of such
Seller’s obligations under this Agreement and the consummation of the transactions contemplated hereby do not and will not, conflict with or result in a violation or breach of any term or provision of any contract, law, order, permit, statute,
rule, or regulation applicable to such Seller. 
 4.2. Title to the Shares. Immediately prior to the Closing Date, such
Seller has good title to, the right to possession of, interest (legal and beneficial) in, and the right to sell such Seller’s Redeemed Shares as listed on Exhibit A and that, such Redeemed Shares shall be transferred, on the Closing Date, to
the Company free and clear of any pledge, lien, security interest, encumbrance, equitable interest or other restrictions or potentially adverse claim of any kind or nature. 

4.3. Third-Party Consents. With respect to such Seller, no consent, approval, authorization and order from any third
parties are required for the execution and delivery of this Agreement or to carry out the transactions contemplated by this Agreement. 

4.4. Authority. Such Seller has full legal right, power and authority to enter into and perform such Seller’s
obligations under this Agreement and to transfer the Redeemed Shares under this Agreement. 
 4.5. Sophisticated
Seller. Such Seller (a) is a sophisticated individual or entity familiar with transactions similar to those contemplated by this Agreement, (b) has adequate information concerning the business and financial condition of the Company
to make an informed decision regarding the sale of the Redeemed Shares, (c) has independently and without reliance upon the Company, and based on such information and the advice of such advisors as such Seller has deemed appropriate, made its
own analysis and decision to enter into this Agreement. Such Seller acknowledges that neither the Company nor its affiliates is acting as a fiduciary or financial or investment adviser to such Seller, and has not given Seller any investment advice,
opinion or other information on whether the sale of the Redeemed Shares is prudent. Such Seller acknowledges that (i) the Company currently may have, and later may come into possession of, information with respect to the Company that is not
known to such Seller and that may be material to a decision to sell the Redeemed Shares (“Seller Excluded Information”), (ii) such Seller has determined to sell the Redeemed Shares notwithstanding its lack of knowledge of Seller
Excluded Information and (iii) the Company shall have no liability to such Seller, and such Seller waives and releases any claims that it might have against the Company whether under applicable securities laws or otherwise, with respect to the
nondisclosure of Seller Excluded Information in connection with the sale of the Redeemed Shares and the transactions contemplated by this Agreement. Such Seller understands that the Company will rely on the accuracy and truth of the foregoing
representations, and such Seller hereby consents to such reliance. 
 4.6. Enforceability. This Agreement constitutes
the legally valid and binding obligation of such Seller, enforceable against such Seller in accordance with its terms, except as may be limited by bankruptcy, insolvency, organization, moratorium or similar laws relating to or affecting
creditors’ rights generally (including, without limitation, fraudulent conveyance laws) and by general principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible
unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding in equity or at law. 

  
 4 

 4.7. Taxes. Such Seller is aware of the tax consequences associated
with the transfer of the Redeemed Shares under this Agreement. Such Seller acknowledges that the Company has advised such Seller that there may be adverse tax consequences to such Seller in consummating the sale of the Redeemed Shares. Such Seller
also acknowledges that the Company has advised such Seller that (a) such tax consequences will vary with such Seller’s particular circumstances, applicable state tax laws and, in some cases, local tax laws, and (b) such Seller should
consult its tax advisor regarding all tax consequences relating to the sale of the Redeemed Shares. The Company makes no representations or warranties with respect to the tax consequences of the sale of the Redeemed Shares. Such Seller agrees and
understands that such Seller alone is responsible for the payment of all local, state and/or federal taxes on the payments and any other consideration provided under this Agreement by the Company and any penalties or assessments thereon. 

4.8. No Reliance. Such Seller acknowledges and agrees that neither the Company, nor any of its stockholders, officers,
directors, employees, or agents (other than such Seller as set forth herein) have (i) acted as an agent, finder or broker for such Seller or such Seller’s agents with respect to the offer, redemption and/or sale of the Redeemed Shares,
(ii) made any representations or warranties of any kind, express or implied, to such Seller or such Seller’s agents in connection with the offer, redemption and/or sale of the Redeemed Shares (other than as set forth herein) or
(iii) at any time had any duty to such Seller or such Seller’s agents to disclose any information relating to the Company, its business, or financial condition or relating to any other matters in connection with the offer, redemption
and/or sale of the Redeemed Shares. In making such Seller’s decision to sell the Redeemed Shares, such Seller is relying solely on their own knowledge and experience and the representations and warranties of the Company set forth in
Section 5 hereof. 
 4.9. Acknowledgements. Such Seller acknowledges and agrees that (i) the value of the
Redeemed Shares may significantly appreciate over time; (ii) the price at which the Company is offering to redeem the Redeemed Shares may not be the highest price that such Seller could obtain for the Redeemed Shares in the future; and
(iii) such Seller is giving up the opportunity to sell the Redeemed Shares at a higher price and to receive the benefit of future appreciation, if any, in the value of the Redeemed Shares. Such Seller further represents that such Seller has had
an opportunity to ask questions and receive answers from the Company regarding the business, properties, prospects and financial condition of the Company, including, without limitation, any strategic transaction, public securities offering, private
financing transaction (whether debt or equity), merger, consolidation, recapitalization, reclassification or similar transaction which have been, are being or may be contemplated by the Company; provided, however, that the foregoing shall not limit
such Seller’s right to rely upon the representations and warranties of the Company contained in Section 5 hereof. Such Seller is aware that (a) the Company may sell in the future its shares of Common Stock and/or Preferred Stock at a
price substantially higher than the 

  
 5 

 
Purchase Price, and (b) if the Company is either sold or consummates a public offering in the future, the consideration received by holders of the Company’s Common Stock and/or
Preferred Stock in connection with such transaction or the initial public offering price in such public offering, as the case may be, may be substantially greater than the Purchase Price. 

ARTICLE 5. 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

In connection with and as an inducement to Shareholders to enter into this Agreement, the Company represents and warrants to Shareholders
that, as of the Closing Date: 
 5.1. Authority. The Company has the full power and authority to enter into, execute
and deliver this Agreement and to consummate the transactions contemplated hereby and any instruments or agreements required herein. 

5.2. Execution and Enforceability. This Agreement has been duly executed and delivered by the Company and constitutes a
valid and binding obligation of the Company enforceable in accordance with its terms subject to the enforcement of equitable remedies, bankruptcy, insolvency, moratorium and other laws affecting the rights of creditors generally and the judicial
limitations of the performance of the remedy of specific performance. 
 ARTICLE 6. 

CONDITIONS TO CLOSING 

6.1. The Company. The obligation of the Company to close the purchase of the Redeemed Shares is subject to and contingent
upon the following conditions, which, at the sole discretion of the Company, may be waived in whole or in part, but if not waived and not fulfilled, will afford the Company the option to terminate this Agreement by written notice delivered to
Sellers at or before the Closing: 
 (a) Seller’s Representations and Warranties. The
representations and warranties of Sellers set forth in Article 4 of this Agreement shall be true and correct in all material respects on the Closing Date. 

(b) Seller’s Performance. Each Seller shall have performed all covenants, obligations and agreements
contained in this Agreement to be performed and complied with by such Seller on or before the Closing Date. 
 (c) Closing
on Sale of Series A2 Preferred Stock. The Company shall have closed on the sale of 20,000,000 shares of Series A2 Preferred Stock to ElevateBio, LLC and received at least $30,000,000 in gross proceeds (the “Financing”).

 (d) Litigation. There shall not be any action, suit or proceeding involving the parties to this Agreement, or
otherwise pending before any court or quasi-judicial or administrative agency of any federal, state, local or foreign jurisdiction, or before an arbitrator, in which an unfavorable injunction, judgment, order, decree, ruling or charge would
(i) prevent the closing of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following the Closing, or (iii) affect adversely the right of the Company
with respect to its redemption or ownership of the Redeemed Shares. 

  
 6 

 6.2. Sellers. The obligation of Sellers to close the sale of the
Redeemed Shares is subject to and contingent upon the following conditions, which, at the sole discretion of each Seller, may be waived in whole or in part, but if not waived and not fulfilled, will afford each Seller the option to terminate this
Agreement by written notice received by the Company before the Closing: 
 (a) Company’s
Representations and Warranties. The representations and warranties of the Company set forth in Article 5 of this Agreement will be true and correct in all material respects on the Closing Date. 

(b) Company’s Performance. The Company shall have performed all covenants, obligations and agreements
contained in this Agreement to be performed and complied with by the Company on or before the Closing Date. 
 ARTICLE 7. 

DELIVERY OF DOCUMENTS 
 On
the Closing Date, the following documents, instruments and agreements shall be executed and/or delivered: 
 7.1. By the Company:

 (a) the Closing Payment shall be paid to Sellers prorata in accordance with their respective Redemption Price shown on
Exhibit A. 
 (b) such other documents and instruments as reasonably requested by Sellers. 

7.2. By Sellers: 

(a) the original certificates, if any, evidencing all of the Redeemed Shares, free and clear of all liens, encumbrances,
security interests and other defects in title. 
 (b) an assignment separate from certificate in the form attached hereto as
Exhibit C from each Seller for such Seller’s respective Redeemed Shares in favor of the Company. 
 (c) such other
documents and instruments as reasonably requested by the Company. 
 ARTICLE 8. 

COVENANTS 
 8.1.
Confidentiality. The parties agree to maintain the confidentiality of the terms of this Agreement, except that each party may disclose the terms of this Agreement to his or her family members, accountants, attorneys and financial
advisors. 

  
 7 

 8.2. Cooperation. Prior to the Closing, the parties hereto shall use
their respective commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done and cooperate with each other in order to do, all things necessary, proper or advisable (subject to any applicable laws) to
consummate the Closing and the transactions contemplated hereby as promptly as practicable. 
 ARTICLE 9. 

TERMINATION 

9.1. Termination. This Agreement may be terminated as follows: 

(a) by mutual written consent of all of the parties hereto at any time prior to the Closing Date; 

(b) if any of the conditions contained in Article 6 are not satisfied or waived prior to the Closing Date; 

(c) by the Company, in the event of a material breach by any Seller of any provision of this Agreement if such breach has not
been (a) waived in writing by the Company, or (b) cured by such Seller to the reasonable satisfaction of the Company within 5 days after delivery by the Company to such Seller of a written notice which describes in detail the breach; or

 (d) by Seller’s collectively, in the event of a material breach by the Company of any provision of this Agreement if
such breach has not been (a) waived in writing by Sellers holding a majority of the shares of Series A1 Preferred, or (b) cured by the Company to the reasonable satisfaction of Sellers holding a majority of the shares of Series A1
Preferred within 10 days after delivery by Sellers to the Company of a written notice which describes in detail the breach. 
 9.2.
Effect of Termination. If this Agreement is terminated as provided above, (a) this Agreement shall forthwith become void and of no further force and effect, and (b) the parties shall be released from any and all obligations
hereunder. 
 ARTICLE 10. 

RELEASES 
 10.1.
Release by Sellers. As of the date of each payment to a Seller hereunder, such Seller absolutely and unconditionally, releases and forever discharges the Company and its shareholders, directors, officers, employees, agents, attorneys,
predecessors prior to conversion to a corporation, successors and assigns, of and from any and all claims, demands, obligations (other than the payment obligations hereunder), interests, suits, actions or causes of action, at law or in equity,
whether arising by contract, statute, common law or otherwise, both direct and indirect, known or unknown, of whatsoever kind or nature, arising or accruing on or prior to the date of such payment. 

10.2. Release in Connection with Closing Payment and Earnout Payment. Each Shareholder acknowledges and agrees that
(a) the Closing Payment will only be paid to Sellers in 

  
 8 

 
accordance with their respective Redemption Price as shown on Exhibit A, (b) the Earnout Payment will only be paid to Sellers in accordance with their respective Prorata Percentages as shown
on Exhibit A, and (c) the Shareholders listed on Exhibit B (i) have no right, title or interest in or to a Closing Payment or an Earnout Payment, (ii) shall not receive any portion of the Closing Payment or the Earnout Payment, and
(iii) knowingly and intentionally waive and release any claim to any portion of the Closing Payment and the Earnout Payment. 

10.3. Indemnification by Sellers. Each Seller shall defend, indemnify and hold harmless the Company and its shareholders,
directors, officers, employees, agents, attorneys, successors and assigns (the “Company Indemnified Parties”) from and against any and all liabilities, losses, damages, claims, costs, expenses, interest, awards, judgments and
penalties, including, without limitation, all reasonable attorneys’ and consultants fees and expenses (collectively “Losses”), suffered or incurred by the Company Indemnified Parties arising out of, relating to or resulting
from (a) the inaccuracy of any representation or warranty made by such Seller in this Agreement, and (b) the breach by such Seller of any covenant or agreement in this Agreement. 

ARTICLE 11. 
 GENERAL
PROVISIONS 
 11.1. Compliance with Laws and Regulations. The sale and transfer of the Redeemed Shares will be
subject to and conditioned upon compliance by the Company and each Seller with all applicable state and federal laws and regulations. 

11.2. Expenses. Each party shall pay its own costs and expenses incurred in connection with this Agreement and the
transaction contemplated hereby, including, without limitation, any attorney’s fees, accounting fees, broker’s fees, finder’s fees, and commissions. 

11.3. No Assignment. No party may assign his or its rights or obligations under the Agreement without the prior written
consent of the other party. Notwithstanding the foregoing, a Seller’s right to receive Earnout Payments pursuant to the terms and conditions of this Agreement may not be assigned. 

11.4. Binding Effect. All the terms and provisions of this Agreement shall be binding upon and insure to the benefit of
and be enforceable by the personal representatives, and permitted successors and assigns of the parties. 
 11.5.
Counterparts. This Agreement may be executed in any number of counterparts, each of which may be executed by less than all of the parties, all of which together will constitute one instrument and will be enforceable against the
parties. This Agreement may be executed by facsimile signature or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com), such signature is deemed an original signature. Copies of the execution copy of
this Agreement or any amendment with one or more signatures sent by facsimile transmission or as a “PDF” (portable document file) attached to an electronic mail message or other transmission method and any counterpart so delivered is
deemed to have been duly and validly delivered and are valid, fully enforceable, and effective for all purposes without a manually executed original. 

  
 9 

 11.6. Changes. This Agreement may not be amended, changed, modified or
altered unless in writing and executed by the Company and the holders of a majority of the Shares. 
 11.7. Governing
Law. This Agreement shall be governed and interpreted in accordance with the laws of the State of Delaware, without giving effect to that body of laws pertaining to conflict of laws. 

11.8. Section Headings. The Section headings of this Agreement are for the convenience of the parties only and in no way
alter, modify, amend, limit, or restrict the contractual obligations of the parties. 
 11.9. Severability; Waiver. The
invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. If any provision of this Agreement is determined to be overbroad as written, that provision
should be deemed amended to narrow its application to the extent necessary to make the provision enforceable according to applicable law and enforced as amended. Any waiver by a party to declare a breach or seek any remedy available to it under this
Agreement or by law will not constitute a waiver as to any past or future breaches or remedies. 
 11.10. Entire
Agreement. This document contains the entire understanding and agreement between the parties with respect to the subject matter set forth herein, and all prior agreements, understandings, discussions, covenants, promises, warranties and
representations, oral or written, express or implied, not incorporated herein are superseded hereby. 
 11.11. No Third Party
Beneficiary. This Agreement is solely for the benefit the Company and Shareholders and does not confer any rights to any other party as a third party beneficiary or otherwise. 

11.12. Time of the Essence; Good Faith. Time is of the essence for this Agreement. Whenever exercising discretion under
this Agreement, each party shall act in good faith. 
 11.13. Interpretation of Agreement. Despite the possibility that
one party or its representatives may have prepared the initial draft of this Agreement or played a greater role in the preparation of subsequent drafts, the parties agree that neither of them will be deemed the drafter of this Agreement and that, in
construing this Agreement, no provision will be construed in favor of one party on the ground that such provision was drafted by the other. If any claim is made by a party relating to any conflict, omission, or ambiguity in the provisions of this
Agreement, no presumption or burden of proof or persuasion will be implied because this Agreement was prepared by or at the request of either party or its counsel. 

11.14. Acknowledgment. The parties acknowledge that the law firm of Winthrop & Weinstine, P.A. represented the
Company and not Shareholders in negotiating and drafting this Agreement. Shareholders further acknowledges that Winthrop & Weinstine, P.A. has encouraged Shareholders to seek separate legal counsel because of actual and/or potential
conflicts of interest which exist, or which may arise in the future, and that Shareholders have in fact received or has had the opportunity to receive separate counsel. 

[signature page follows] 

  
 10 

 IN WITNESS WHEREOF, the parties to this Redeemable Preferred Stock Redemption Agreement have
executed and delivered this Agreement as of the date first set forth above. 
  

			
	VIRACYTE, INC.
	
	 /s/ John Wilson

	John Wilson
	President

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of September 17, 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and 

(B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of September 17, 2018, by and among
ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned further agrees and
authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 

 

	
	SHAREHOLDER:
	
	  

	Date:

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 		 	
	Name of Entity	 		 	By:	 	 /s/ Ali Behbahani

					
	By:	 	  
	 		 	Name:	 	 Ali Behbahani

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 	  

		 		 	  

			
	Address:	 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Andrew Arthur

					
	By:	 	  
	 		 	Name:	 	 Andrew Arthur

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 	  

		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
				
	  
	 		 		 	
	Name of Entity	 		 	By:	 	 /s/ Ann Leen

					
	By:	 	  
	 		 	Name:	 	 Ann Leen

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 	  

				
	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Bambi Grilley

					
	By:	 	  
	 		 	Name:	 	 Bambi Grilley

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
			
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Brett H Larson

					
	By:	 	  
	 		 	Name:	 	 Brett H Larson

					
	Name:	 	  
	 		 	Date:	 	 8/28/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

				
		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Dan Welch

					
	By:	 	  
	 		 	Name:	 	 Dan Welch

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Daniel E. Lee

					
	By:	 	  
	 		 	Name:	 	 Daniel E. Lee

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Devan V. Padmanabhan

					
	By:	 	  
	 		 	Name:	 	 Devan V. Padmanabhan

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
			
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Eliot Laurence

					
	By:	 	  
	 		 	Name:	 	 Eliot Laurence

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 21 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
			
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Helen Heslop

					
	By:	 	  
	 		 	Name:	 	 Helen Heslop

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 		 	
	Name of Entity	 		 	By:	 	 /s/ Ifigeneia Tzannou

					
	By:	 	  
	 		 	Name:	 	 Ifigeneia Tzannou

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Jacqueline Christman

					
	By:	 	  
	 		 	Name:	 	 Jacqueline Christman

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ James Hannigan

					
	By:	 	  
	 		 	Name:	 	 James Hannigan

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Joe Dziedzic

					
	By:	 	  
	 		 	Name:	 	 Joe Dziedzic

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	Address
		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (C) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (D) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ John Wilson

					
	By:	 	  
	 		 	Name:	 	 John Wilson

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	
		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof: it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “ Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counter part, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Juan Vera

					
	By:	 	  
	 		 	Name:	 	 Juan Vera

					
	Name:	 	  
	 		 	Date:	 	  

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	
		 		 		 	
		 		 		 	
	Address:	 		 		 	
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Kruti Patel

					
	By:	 	  
	 		 	Name:	 	 Kruti Patel

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
			
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Madeline Giroir

					
	By:	 	  
	 		 	Name:	 	 Madeline Giroir

					
	Name:	 	  
	 		 	Date:	 	 8/31/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Peter Hoang

					
	By:	 	  
	 		 	Name:	 	 Peter Hoang

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Reed A. Smith

					
	By:	 	  
	 		 	Name:	 	 Reed A. Smith

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
				
	 Salt Free LP
	 		 		 	
	Name of Entity	 		 	By:	 	  

					
	By:	 	 /s/ Malcolm K. Brenner
	 		 	Name:	 	  

					
	Name:	 	 Malcolm K. Brenner, MB, PhD
	 		 	Date:	 	  

				
	Title:	 	 Managing Partner
	 		 	Address:
				
	Date:	 	 8/27/2018
	 		 	  

	[***]	 		 		 	  

		 		 		 	
	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
			
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Stephen Dziedzic

					
	By:	 	  
	 		 	Name:	 	 Stephen Dziedzic

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Stephen Handley

					
	By:	 	  
	 		 	Name:	 	 Stephen Handley

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	 [***]

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Sunitha Kakarla

					
	By:	 	  
	 		 	Name:	 	 Sunitha Kakarla

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	[***]
		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August     , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
			
	  
	 		 	
	Name of Entity	 		 	
				
	By:	 	  
	 		 	 /s/ Ulrike Gerdemann

					
	By:	 	  
	 		 	Name:	 	 Ulrike Gerdemann

					
	Name:	 	  
	 		 	Date:	 	 8/27/2018

		 		 		 	  

		 		 		 	  

	Address:	 		 		 	
	  
	 		 		 	
	  
	 		 		 	
					
	 Title:
	 	  
	 		 		 	
					
	 Date:
	 	  
	 		 		 	

  
 13 

 Combined Signature Page 

By execution and delivery of this signature page, the undersigned hereby agrees that, if not already a party to and bound by, as of the date
hereof, it is a party to and bound by the terms and conditions of the following agreements (in the capacities indicated): 
 (A) the
Redeemable Preferred Stock Redemption Agreement (the “Redemption Agreement”), dated as of August    , 2018, by and among ViraCyte, Inc., a Delaware corporation and the parties thereto, as a “Shareholder”; and

 (B) the Series A2 Preferred Stock Purchase Agreement (the “Purchase Agreement”), dated as of August     ,
2018, by and among ViraCyte, Inc., a Delaware corporation, the Shareholders party thereto, and ElevateBio, LLC, as a “Seller”. 
 The undersigned
further agrees and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof, and to the Redemption Agreement, or counterparts thereof. 

Executed, in counterpart, as of the date set forth below. 
  

									
		 		 	SHAREHOLDER:
			
	If entity:	 		 	If individual:
			
	  
	 		 	
	Name of Entity	 		 	By:	 	 /s/ Walter Dziedzic

					
	By:	 	  
	 		 	Name:	 	 Walter Dziedzic

					
	Name:	 	  
	 		 	Date:	 	 8-27-2018

				
	Title:	 	  
	 		 	Address:
				
	Date:	 	  
	 		 	
		 		 		 	
		 		 		 	
	Address:	 		 		 	
				
	  
	 		 		 	
				
	  
	 		 		 	

  
 13 

 EXHIBIT A 
  

																	
	 Shareholder
	  	Redeemable
Preferred
Stock
Redeemed	 	  	Redemption
Price	 	  	Series A1
Preferred
Stock	 	  	Earnout
Payment
Percentage	 
	Sellers	  				  				  				  			
	 Wilson, John
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Leen, Ann
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Vera, Juan
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Salt Free LP
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Heslop, Helen
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Dziedzic, Stephen
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Laurence, Eliot
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Arthur, Andrew
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Handley, Stephen
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Hannigan, James
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Smith, Reed A.
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Padmanabhan, Devan V.
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Dziedzic, Joe
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Welch, Dan
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Dziedzic, Walter
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Lee, Daniel E.
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Larson, Brett
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
		  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Shareholders Not Sellers
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Jacqueline Christman
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Madeline Giroir
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Sunitha Kakarla
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Kruti Patel
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Ifigeneia Tzannou
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Bambi Grilley
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Ali Behbahani
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Peter Hoang
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 
	 Ulrike Gerdemann
	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 	  	 	[***]	 

 Redeemable Preferred Stock Redemption Agreement 

 EXHIBIT B 

Jacqueline Christman 
 Madeline Giroir 

Sunitha Kakarla 
 Kruti Patel 

Ifigeneia Tzannou 
 Bambi Grilley 

Ali Behbahani 
 Peter Hoang 

Ulrike Gerdemann 

 EXHIBIT C 

STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto ViraCyte, Inc., [# of shares] shares of the Redeemable Preferred
Stock of ViraCyte, Inc., a Delaware corporation, standing in his name on the books of the corporation. The undersigned does hereby irrevocably constitute and appoint the corporation as its attorney-in-fact to transfer the shares on the books of the corporation with full power of substitution in the premises. 
  

							
	 Dated:
	 	  
	 		 	
				
		 		 		 	  

		 		 		 	 Signature

		 		 		 	  

		 		 		 	 Print NameEX-10.14

 Exhibit 10.14 

AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT 

This Amended and Restated Executive Employment Agreement (this “Agreement”) is entered into between Allovir, Inc.,
f/k/a ViraCyte Inc., a Delaware corporation (“Company”) and David Hallal (“Employee”). This Agreement is effective as of the later of (i) the date the Agreement becomes fully executed by
the parties; or (ii) ten (10) business days after the Company provides Employee with the Restrictive Covenants Agreement (as defined below) (the “Effective Date”). 

WHEREAS, the Company and Employee are parties to a Consulting and Executive Employment Agreement entered into on December 3, 2018 (the
“Prior Agreement”); 
 WHEREAS, the Company and Employee desire to fully supersede and replace the Prior Agreement
with this Agreement; provided that the Company and Employee desire to preserve Exhibit A to the Prior Agreement, the Restricted Stock Agreement, and any exhibits and/or attachments thereto, and Exhibit B to the Prior Agreement, the Employee
Invention Assignment and Confidentiality Agreement, and any exhibits and/or attachments thereto, (with Exhibit A and Exhibit B to the Prior Agreement referred to collectively as the “Prior Exhibits”) and acknowledge and agree
that such Prior Exhibits (and any exhibits and/or attachments thereto) shall remain in full force and effect both during and after Employee’s employment relationship with the Company; 

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby confirmed, the Company and Employee agree as follows: 

1. Position and Duties. The Company will continue to employ Employee as the Chief Executive Officer of the
Company. Employee will report to the Company’s Board of Directors (the “Board”) and will render such business and professional services in the performance of his duties, consistent with Employee’s position, as shall
reasonably be assigned to him by the Board. 
 2. Board Service. Employee will continue to serve as Chairman of
the Board and shall be re-elected so long as Employee is employed by the Company in the capacity of Chief Executive Officer. Employee may be removed from the Board in accordance with applicable law and the Company’s bylaws. If Employee ceases
to be employed by the Company, Employee will resign from all Board positions at the request of the Board. 
 3.
Service to the Company. Except as otherwise specified herein, Employee will be expected to devote his full working time and attention to the business of the Company, and will not render services to any other business without the prior
approval of the Board or, directly or indirectly, engage or participate in any business that is competitive in any manner with the business of the Company; provided, however, that Employee may continue to serve on the boards of directors and
advisory boards on which he presently serves, all of which have been disclosed to the Company, and may serve on additional boards (whether advisory or boards of directors) with the prior approval of the Board, not to be unreasonably withheld. The
Company acknowledges that Employee is a party to an employment agreement with ElevateBio Management, Inc., (“ElevateBio”) and will devote a portion of his working time to ElevateBio and its subsidiaries and affiliates. Employee will also
be expected to comply with and be bound by the Company’s operating policies, procedures and practices that are from time to time in effect during the term of his employment and are provided to Employee. 

  
 1 

 4. At-Will Employment. Employee and the Company understand and
acknowledge that Employee’s employment with the Company constitutes “at-will” employment, and the employment relationship may be terminated at any time, with or without cause and with or without notice. 

5. Compensation and Benefits. 

5.1 Base Salary. The Company shall pay the Employee an annual base salary of $550,000 (as adjusted from time to time in
accordance with the terms hereof, the “Base Salary”), payable in accordance with the Company’s normal payroll practices. The Board shall periodically review (at least annually) Employee’s Base Salary, provided that
any changes thereto shall be determined by the Board in its sole and absolute discretion. 
 5.2 Corporate Objectives
Bonus. Employee will be eligible to receive an annual cash bonus with a target bonus opportunity of 50% of Employee’s then current Base Salary (the “Target Annual Bonus”), upon the achievement of annual corporate
performance goals determined by the Board. Annual corporate performance goals shall be determined no later than the end of January of the performance year, which generally shall be coincident with the calendar year. The Board, at its sole
discretion, may increase Employee’s Annual Bonus or award an additional bonus to the Employee for extraordinary service to the Company. To receive payment of any bonus Employee must be employed by the Company at the time bonuses are paid. 

5.3 Employee Benefits. Employee shall be eligible to participate in all employee benefit plans and arrangements,
including, but not limited to, medical, dental, vision and long-term disability insurance benefits and arrangements, as are made available by the Company to its other senior executives, subject to the terms and conditions thereof. 

5.4 Vacation. Employee will be entitled to paid vacation (in addition to Company holidays) pursuant to the terms of the
Company’s vacation policy as may exist from time to time. 
 6. Equity Matters. All equity awards Employee
received or may be eligible to receive from the Company shall be governed by the terms of such awards’ applicable restrictive stock agreements and plan documents, including, but not limited to, the 2019 AlloVir (formerly ViraCyte) Stock Plan,
(collectively, and as any may be amended, the “Equity Documents”); notwithstanding the provisions in the Equity Documents, in the event of a Sale Event as that term is defined in the 2019 AlloVir (formerly ViraCyte) Stock
Plan all unvested equity shall vest upon the closing of such a Sale Event. 
 7. Expenses. The Company will, in
accordance with applicable Company policies and guidelines, reimburse Employee for all reasonable and necessary expenses incurred by Employee in connection with his performance of services on behalf of the Company. 

  
 2 

 8. Inventions and Proprietary Information, Non-Competition. In
exchange for, among other things, a one-time, lump-sum payment of $5,000, which Employee acknowledges and agrees is fair and reasonable consideration that is independent from the continuation of employment with the Company, Employee agrees to the
terms of the Restrictive Covenants Agreement attached to this Agreement as Exhibit A (the “Restrictive Covenants Agreement”), which is hereby incorporated by reference into this Agreement. Employee acknowledges and
understands that he has been advised by the Company that he has the right to consult with counsel prior to signing the Restrictive Covenants Agreement. Employee further acknowledges and agrees that Employee received the Restrictive Covenants
Agreement at least ten (10) business days before the Restrictive Covenants Agreement is to become effective. 

9. Definitions. 

9.1 Cause. For purposes of this Agreement, “Cause” means the occurrence of any of the following
after the Effective Date (i) Employee’s persistent failure to carry out any material lawful duties of Employee or any lawful directions of the Board reasonably consistent with Employee’s duties; provided, however, that Employee
has been given reasonable notice of the specific failure and an opportunity to correct such failure within thirty (30) business days from the date of the notice; (ii) Employee’s conviction of or plea of nolo contendere
to a felony, which has had or will have a detrimental effect on the Company’s reputation or business, (iii) Employee engaging in an act of gross negligence or willful misconduct in the performance of his employment obligations and
duties, (iv) Employee’s commission of an act of fraud against the Company or willful misappropriation of property belonging to the Company; (v) Employee engaging in any other willful misconduct that has caused or will
cause material harm to the Company’s reputation or business; or (vi) Employee’s material breach of the Restrictive Covenants Agreement or the Prior Exhibits. No act or failure to act will be considered “willful”
unless Employee has acted, or failed to act, with a lack of good faith and with a lack of reasonable belief that Employee’s action or failure to act was in the best interest of the Company or any of its affiliates. 

9.2 Disability. For purposes of this Agreement “Disability” shall have that meaning set forth in
Section 22(e)(3) of the Internal Revenue Code of 1986, as amended (the “Code”). 
 9.3
Good Reason. For purposes of this Agreement, “Good Reason” means any of the following actions that have been taken by the Company without Employee’s written consent, provided that (a) the Company
receives, within ninety (60) days following Employee’s knowledge of the occurrence of any of the conditions or events set forth in clauses (i) through (v) below, written notice from Employee specifying the specific basis
for Employee’s belief that Employee is entitled to terminate employment for Good Reason, (b) the Company fails to cure the condition or event constituting Good Reason within thirty (30) days after receipt of such written
notice thereof, and (c) Employee terminates employment within thirty (30) days following expiration of such cure period: 

  
 3 

 (i) A material diminution in Employee’s responsibilities, authority, or
duties; 
 (ii) A material diminution in Employee’s Base Salary except for across-the-board salary reductions based on
the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company; 

(iii) A material change in the geographic location at which Employee provides services to the Company, such that there is an
increase of at least thirty (30) miles of driving distance to such location from the Executive’s principal place of residence as of such change; or 

(iv) A material breach of this Agreement by the Company. 

10. Effect of Separation from Service. For purposes of this Agreement, no payment will be made to Employee upon
termination of Employee’s employment unless such termination constitutes a “separation from service” within the meaning of Section 409A of the Code, and Section 1.409A-1(h) of the regulations
promulgated thereunder. 
 10.1 Separation for Cause, Death, Disability or Voluntary Separation from Service. In the
event of Employee’s separation from service from the Company for Cause or in the event of Employee’s death, Disability or voluntary separation from service at any time and for any reason, Employee or his estate will be paid only
(i) any earned but unpaid Base Salary, (ii) other unpaid vested amounts or benefits under the compensation, incentive and benefit plans of the Company in which Employee participates (including accrued vacation earned through his
separation from service), and (iii) reimbursement for all reasonable and necessary expenses incurred by Employee in connection with his performance of services on behalf of the Company in accordance with applicable Company policies and
guidelines, in each case as of the effective date of such separation from service (the “Accrued Compensation”). In the event of Employee’s death or Disability, any unvested stock option held by Employee shall be
accelerated in vesting in an amount equal to (i) twenty five percent (25%) plus (ii) five percent (5%) for each year of service to the Company of the total number of shares covered by the option. Employee or his estate will
be allowed to exercise his vested stock options to purchase the Company’s common stock, if any, during the time period set forth in, and in accordance with, the Company’s 2018 Equity Incentive Plan and governing stock option agreements.

 10.2 Separation from Service without Cause or for Good Reason. In the event of Employee’s separation from
service from the Company without Cause or for Good Reason, and provided that Employee delivers to the Company a signed separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a
general release of claims against the Company and all related persons and entities, a reaffirmation of all of the Employee’s Continuing Obligations (as defined below), and, in the Company’s sole discretion, a one-year post-employment
non-competition restriction in a form substantially similar to the Non-Competition Restriction (as defined in the Restrictive Covenants Agreement attached hereto as Exhibit A) (the “Separation Agreement and
Release”), and (ii) the Separation Agreement and Release becoming irrevocable all within sixty (60) days following Employee’s separation from service (or such shorter period as set forth in the Separation
Agreement and Release), which shall include a seven (7) business day revocation period, then, in addition to the Accrued Compensation, Employee shall be entitled to the following: 

  
 4 

 (i) A lump sum payment equal to (a) twenty-four (24) months
so long as the Company is a privately-owned company or (b) thirty-six (36) months if the Company becomes a publicly-traded company on the NASDAQ or NYSE (in either case, the “Severance Period”) of the
Employee’s then current Base Salary payable on the sixty-first (61st) day following the date of Employee’s separation from service; 

(ii) A lump sum payment for Target Annual Bonus payable on the sixty-first (61st) day following the date of Employee’s
separation from service (collectively, with the payment provided for in Section 10.2(i), the “Severance Amount”); 

(iii) Notwithstanding in the foregoing, in the event Employee is entitled to any payments pursuant to the Restrictive Covenants
Agreement, the Severance Amount will be reduced by the amount Employee is paid pursuant to the Restrictive Covenants Agreement; 

(iv) Provided Employee timely elects to continue health coverage under the Consolidated Omnibus Budget Reconciliation Act of
1985, as amended (“COBRA”), reimbursement for any monthly COBRA premium payments made by Employee for Employee and his eligible dependents until the earliest of (a) the expiration of the Severance Period;
(b) Employee’s eligibility for group medical plan benefits under any other employer’s group medical plan; or (c) the cessation of Employee’s continuation rights under COBRA; provided, however, if the Company
determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service
Act), then the Company shall convert such payments to payroll payments directly to Employee for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll
dates. For the avoidance of doubt, the taxable payments described above may be used for any purpose, including, but not limited to, continuation coverage under COBRA; and, 

(v) Notwithstanding the provisions of Section 6, all unvested and earned equity awards held by Employee at the time of
such separation from service shall accelerate in vesting and, as applicable, become fully exercisable and all stock options will remain exercisable thereafter in accordance with the terms of the applicable award agreement. 

10.3 Parachute Payments. In the event that any payments or benefits provided for in this Agreement or otherwise payable
to Employee (collectively, the “Payments”) (i) constitute “parachute payments” within the meaning of Section 280G of the Code and (ii) but for this Section, would be subject to
the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable either (i) in full, or (ii) as to such lesser amount which would result in no portion of the Payments being subject to the
excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in the receipt by Employee
on an after-tax basis, of the greatest amount of Payments, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. Any reduction to the Payments required under this Section shall
be made by the Company in its reasonable discretion in the following order and in a manner intended to comply with Section 409A of the Code (as determined by the Company): (i) payments that are payable in cash that are valued at full
value under Treasury Regulation Section 1.280G-1, Q&A 24(a) will be reduced (if necessary, to zero), with amounts that are payable last reduced first; (ii) payments and benefits due in respect of any equity valued at full
value under Treasury Regulation Section 1.280G-1, Q&A 24(a), with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&A 24), will next be reduced;
(iii) payments that are payable in cash that are valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with amounts that are payable last reduced first, will next be reduced;
(iv) payments and benefits due in respect of any equity valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with the highest values reduced first (as such values are determined under
Treasury Regulation Section 1.280G-1, Q&A 24), will next be reduced; and (v) all other non-cash benefits not otherwise described in clauses (ii) or (iv) hereof will be next reduced pro-rata. Any reductions
made pursuant to each of clauses (i)-(v) of the immediately preceding sentence will be made in the following manner: first, a pro-rata reduction of cash payment and payments and benefits due in respect of any equity not subject to
Section 409A of the Code, and second, a pro-rata reduction of cash payments and payments and benefits due in respect of any equity subject to Section 409A of the Code as deferred compensation. Unless the Company and Employee
otherwise agree in writing, any determinations required under this Section shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determinations shall be conclusive and
binding upon Employee and the Company for all purposes. The Company shall cause the Accountants to provide its determinations and any supporting calculations with respect to Employee to the Company and Employee. For purposes of making the
calculations required by this Section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the
Code. The Company and Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section. The Company shall bear all costs the Accountants may
reasonably incur in connection with any calculations contemplated by this Section. 

  
 5 

 11. Miscellaneous. 

11.1 Arbitration. Employee and the Company agree to submit to mandatory binding arbitration, in New York, New York, any
and all claims arising out of or related to this Agreement and Employee’s employment with the Company and the termination thereof, except that each party may, at its or his option, seek injunctive relief in court related to the improper use,
disclosure or misappropriation of a party’s proprietary, confidential or trade secret information. EMPLOYEE AND THE COMPANY HEREBY WAIVE ANY RIGHTS TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS. This Agreement to arbitrate does not restrict
Employee’s right to file administrative claims Employee may bring before any government agency where, as a matter of law, the parties may not restrict Employee’s ability to file such claims (including, but not limited to, the National
Labor Relations Board, the Equal Employment Opportunity Commission and the Department of Labor). However, Employee and the Company agree that, to the fullest extent permitted by law, arbitration shall be the exclusive remedy for the subject matter
of such administrative claims. The arbitration shall be conducted through JAMS before a single neutral arbitrator, in accordance with the JAMS employment arbitration rules then in effect. The arbitrator shall issue a written decision that contains
the essential findings and conclusions on which the decision is based. 

  
 6 

 11.2 Indemnification. The Company shall indemnify Employee with
respect to activities in connection with his employment hereunder to the fullest extent provided in the Company’s bylaws. Employee will be named as an insured on the director and officer liability insurance policy currently maintained, or as
may be maintained by the Company from time to time, and, in addition, Employee will enter into the form of indemnification agreement provided to other similarly situated executive officers and directors of the Company. 

11.3 Section 409A. To the extent (i) any payments or benefits to which Employee becomes entitled under this
Agreement, or under any agreement or plan referenced herein, in connection with Employee’s termination of employment with the Company constitute deferred compensation subject to Section 409A of the Code and (ii) Employee
is deemed at the time of such termination of employment to be a “specified employee” under Section 409A of the Code, then such payments shall not be made or commence until the earliest of (a) the
expiration of the six (6)-month period measured from the date of Employee’s “separation from service” (as such term is at the time defined in Treasury Regulations under Section 409A of the Code) from the
Company; or (b) the date of Employee’s death following such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Employee, including (without
limitation) the additional twenty percent (20%) tax for which Employee would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period, any payments
which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph shall be paid to Employee or Employee’s beneficiary in one lump sum (without interest). Any termination of
Employee’s employment is intended to constitute a “separation from service” and will be determined consistent with the rules relating to a “separation from service” as such term is defined in
Treasury Regulation Section 1.409A-1. It is intended that each installment of the payments provided hereunder constitute separate “payments” for purposes of Treasury Regulation
Section 1.409A-2(b)(2)(i). It is further intended that payments hereunder satisfy, to the greatest extent possible, the exemption from the application of Section 409A of the Code (and any state law of similar effect) provided
under Treasury Regulation Section 1.409A-1(b)(4) (as a “short-term deferral”). To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the
provision will be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit
under this Agreement is determined to be subject to Section 409A of the Code, the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect the expenses eligible for
reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses), in no event shall any expenses be reimbursed after the last day of the calendar year following the calendar year in which
Employee incurred such expenses, and in no event shall any right to reimbursement or the provision of any in-kind benefit be subject to liquidation or exchange for another benefit. 

  
 7 

 11.4 Severability. If any provision of this Agreement shall be found
by any arbitrator or court of competent jurisdiction to be invalid or unenforceable, then the parties hereby waive such provision to the extent of its invalidity or unenforceability and agree that all other provisions in this Agreement shall
continue in full force and effect. 
 11.5 No Waiver. The failure by either party at any time to require performance
or compliance by the other of any of its obligations or agreements shall in no way affect the right to require such performance or compliance at any time thereafter. The waiver by either party of a breach of any provision hereof shall not be taken
or held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of the provision itself. No waiver of any kind shall be effective or binding, unless it is in writing and is signed by the party against whom such waiver
is sought to be enforced. 
 11.6 Assignment. This Agreement and all rights hereunder are personal to Employee and may
not be transferred or assigned by Employee at any time. The Company may assign its rights, together with its obligations hereunder, to any purchaser of all or substantially all of its business and assets, provided, however, that any such assignee
assumes the Company’s obligations hereunder. 
 11.7 Withholding. All sums payable to Employee hereunder shall be
in United States Dollars and shall be reduced by all federal, state, local and other withholding and similar taxes and payments required by applicable law. 

11.8 Continuing Obligations. For purposes of this Agreement, the obligations that arise in the Restrictive Covenants
Agreement, the Prior Exhibits, the Equity Documents, and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing
Obligations.” 
 11.9 Amendment. The parties understand and agree that this Agreement may not be amended,
modified or waived, in whole or in part, except in a writing executed by Employee and the Company. 
 11.10 Notices.
All notices, if any, and all other communications, if any, required or permitted under this Agreement shall be in writing and hand delivered, sent via facsimile, sent by registered first class mail, postage pre-paid, or sent by nationally recognized
express courier service. Such notices and other communications shall be effective upon receipt if hand delivered or sent via facsimile, five (5) days after mailing if sent by mail, and one (l) day after dispatch if sent by express
courier, to the following addresses, or such other addresses as any party shall notify the other parties: 

  
 8 

			
	If to the Company:	  	 Allovir, Inc.
 139 Main St., Suite 500

Cambridge, MA 02142
 Attention: General Counsel

		
	If to Employee:	  	The last address on file in the Company’s records.

 11.11 Binding Nature. This Agreement shall be binding upon, and inure to the benefit of,
the successors and personal representatives of the respective parties hereto. 
 11.12 Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which, taken together, constitute one and the same agreement. 

11.13 Governing Law. This Agreement and the rights and obligations of the parties hereto shall be construed in
accordance with the laws of the State of Delaware, without giving effect to the principles of conflict of laws. 
 11.14
Attorneys’ Fees. In the event of any claim, demand or suit arising out of or with respect to this Agreement, the prevailing party shall be entitled to reasonable costs and attorneys’ fees, including any such costs and fees upon
appeal. 
 11.15 Entire Agreement. This Agreement (and the exhibit(s) hereto, including but not limited to the
Restrictive Covenants Agreement) together with the Equity Documents, as amended, and the Prior Exhibits (and any exhibits and/or attachments thereto) constitute the entire and only agreement and understanding between the parties relating to
Employee’s employment with Company. Subject to the foregoing, this Agreement supersedes and cancels any and all previous contracts, arrangements or understandings with respect to Employee’s employment. 

IN WITNESS WHEREOF, the Company and Employee have executed this Amended and Restated Executive Employment Agreement as of the date first above
written. 
  

									
	ALLOVIR, INC.	 		 	David Hallal
			
	 /s/ John Wilson
	 		 	 /s/ David Hallal

					
	Print Name:	 	John Wilson	 		 	Print Name:	 	David Hallal
					
	Title:	 	Director	 		 	Address:	 	
					
	Date:	 	 10/2/2019
	 		 	Date:	 	 10/2/2019

  
 9 

 EXHIBIT A 

EMPLOYEE RESTRICTIVE COVENANTS AGREEMENT 

  
 10 

 EMPLOYEE RESTRICTIVE COVENANTS AGREEMENT 

In exchange for, among other things, a one-time, lump-sum payment of $5,000, which Employee (as defined below) acknowledges and agrees is fair
and reasonable consideration that is independent from the continuation of employment with the Company, David Hallal (“Employee”) with Allovir, Inc., f/k/a ViraCyte, Inc., its subsidiaries, affiliates, successors or assigns (together the
“Company”), enter into this Restrictive Covenants Agreement (this “Agreement”), and hereby agree to the following: 
  

	1.	 Proprietary Information. 

(a) Company Information. Employee agrees at all times during the term of Employee’s employment and thereafter, to
hold in strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person, firm or corporation without written authorization of the Board of Directors of the Company, any Proprietary Information of the
Company, except under a non-disclosure agreement duly authorized and executed by the Company. Employee understands that “Proprietary Information” means any non-public information regarding or relating to the Company or its products
including: (1) the actual or anticipated business or research and development of the Company, technical data, trade secrets or know-how, including, but not limited to, research, product plans or other information regarding the Company’s
products or services and markets therefore; (2) research, clinical or other trials, developments, inventions, processes, formulas, technology, designs, drawings, engineering, software, hardware configuration information, marketing,
finances or other business information; (3) customer lists and customers (including, but not limited to, customers of the Company on whom Employee called or with whom Employee became acquainted during the term of Employee’s
employment); (4) the identity, skills and compensation of employees, consultants, or contractors; (5) policies and procedures of the Company; (6) anything related to Company Inventions (as defined herein); and
(7) Third Party Information (as defined herein). Employee further understands that Proprietary Information does not include any of the foregoing items which have become publicly known and made generally available through no wrongful act
of the Employee or of others who were under confidentiality obligations as to the item or items involved or improvements or new versions thereof. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b),
Employee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a Federal, State, or local government official, either directly
or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under
seal. In addition, notwithstanding the foregoing, Employee shall not be prohibited from disclosing Proprietary Information to a government agency as a whistleblower. 

(b) Third Party Information. Employee recognizes that the Company has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes (“Third Party Information”). Employee
agrees to hold all Third Party Information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out Employee’s work for the Company consistent with the Company’s
agreement with such third party. 

  
 1 

	2.	 Inventions. 

(a) Inventions Retained and Licensed. Employee has attached hereto, as Exhibit 1, a list describing all inventions,
original works of authorship, developments, improvements, and trade secrets which were made by Employee prior to Employee’s employment with the Company (collectively referred to as “Prior Inventions”), which belong to Employee, which
relate to the Company’s proposed business, products or research and development, and which are not assigned to the Company hereunder; or, if no such list is attached, Employee represents that there are no such Prior Inventions. If in the course
of Employee’s employment with the Company, Employee incorporates into a Company product, process or service a Prior Invention owned by Employee or in which Employee has an interest, Employee hereby grants to the Company a nonexclusive,
royalty-free, fully paid-up, irrevocable, perpetual, worldwide license to make, have made, modify, use and sell such Prior Invention as part of or in connection with such product, process or service, and to practice any method related thereto. 

(b) Assignment of Inventions. Employee agrees that Employee will promptly make full written disclosure to the Company,
will hold in trust for the sole right and benefit of the Company, and hereby assign (or, for future inventions, agree to assign) to the Company, or its designee, all Employee’s right, title, and interest in and to any and all inventions,
original works of authorship, writings, developments, concepts, improvements, designs, discoveries, ideas, processes, formulas, data, trademarks or trade secrets, whether or not patentable or registrable under copyright or similar laws, which
Employee may solely or jointly conceive or develop or reduce to practice within the scope of Employee’s employment, or cause to be conceived or developed or reduced to practice, during the period of time Employee is employed by the Company
(collectively referred to as “Inventions”), except as provided in Section 2(f) below. Employee agrees that Company will exclusively own all work product that is made by Employee (solely or jointly with others) within the scope of
Employee’s employment. Employee further acknowledges that all original works of authorship which are made by Employee (solely or jointly with others) within the scope of and during the period of Employee’s employment
with the Company and which are protectable by copyright are “works made for hire,” as that term is defined in the United States Copyright Act. Employee understands and agrees that the decision whether or not to commercialize or market any
Invention developed by Employee solely or jointly with others is within the Company’s sole discretion and for the Company’s sole benefit and that no royalty will be due to Employee as a result of the Company’s efforts to commercialize
or market any such Invention. Employee acknowledges and agrees that nothing in this Agreement shall be deemed to grant, by implication, estoppel or otherwise, a license from the Company to me to make, use, license, or transfer in any way an existing
or future Invention. 
 (c) Inventions Assigned to the United States. Employee agrees to assign to the United States
government all Employee’s right, title, and interest in and to any and all Inventions whenever such full title is required to be in the United States by a contract between the Company and the United States or any of its agencies. 

  
 2 

 (d) Maintenance of Records. Employee agrees to keep and maintain
adequate and current written records of all Inventions made by Employee (solely or jointly with others) during the term of Employee’s employment with the Company. The records will be in the form of notes, sketches, drawings, and any other
format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times. 

(e) Patent and Copyright Registrations. Employee agrees to assist the Company, or its designee, at the Company’s
expense, in every proper way to secure the Company’s rights in the Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company
of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in
order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title and interest in and to such Inventions, and any copyrights, patents, mask work rights or other intellectual property rights
relating thereto. Employee further agrees that Employee’s obligation to execute or cause to be executed, when it is in Employee’s power to do so, any such instrument or papers shall continue after the termination of this Agreement. If the
Company is unable because of Employee’s mental or physical incapacity or for any other reason to secure Employee’s signature to apply for or to pursue any application for any United States or foreign patents or copyright registrations
covering Inventions or original works of authorship assigned to the Company as above, then Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employee’s agent and attorney in fact, to
act for and in Employee’s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal
force and effect as if executed by Employee. 
 (f) Exceptions. This Agreement does not obligate Employee to assign to
the Company any Invention that, in the sole judgment of the Company, reasonably exercised, is developed entirely on my own time and does not relate to the business efforts or research and development efforts in which, during the period of my
employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company. However, Employee will also promptly disclose to the Company any such Inventions
for the purpose of determining whether they qualify for such exclusion. Employee understands that to the extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee
agreement to assign certain classes of inventions made by an employee, this Section 2 will be interpreted not to apply to any invention that a court rules and/or the Company agrees falls within such classes. 

  
 3 

	3.	 Former Employer Information. Employee agrees that Employee will not, during Employee’s
employment with the Company, improperly use or disclose any proprietary information or trade secrets of any former employer or other person or entity and that Employee will not bring onto the premises of the Company any unpublished document or
proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity. Employee further agrees that Employee will not incorporate into any Invention any Proprietary Information or
trade secrets of any former employer or other person or entity. 

  

	4.	 Conflicting Employment. Subject to the forgoing, Employee agrees that, during the term of
Employee’s employment with the Company, Employee will not engage in any other employment, occupation or consulting directly related to the Company’s business, nor will Employee engage in any other activities that conflict with
Employee’s obligations to the Company. 

  

	5.	 Non-Competition. 

(a) In order to protect the Company’s Proprietary Information and goodwill, during Employee’s employment and for a period of
(i) one (1) year following the date of the cessation of Employee’s employment with the Company (the “Last Date of Employment”) or such shorter period as the Company designates in writing to Employee (which designation must be
made no later than the date any waiver must be made under Section 5(b)(iii)), or (ii) two (2) years following the Last Date of Employment if Employee breaches his fiduciary duty to the Company or if Employee has unlawfully taken,
physically or electronically, property belonging to the Company (in either case, the “Restricted Period”), Employee shall not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee,
co-venturer or otherwise, anywhere in the world, engage or otherwise participate in any business that develops, manufactures or markets any products, performs any services, or conducts any research focused on using
T-cell therapy to address viruses or virus-related diseases (the “Noncompetition Restriction”). 

(b) Notwithstanding the foregoing, the Noncompetition Restrictions shall not apply: (i) if the Company terminates Employee’s
employment without “cause” (within the meaning of Mass. Gen. Laws Chapter 149, Sec 24L (c)); (ii) if the Employee has been laid off by the Company; (iii) if the Company waives the Noncompetition Restriction; or (iv) to
Employee’s activities on behalf of ElevateBio Management, Inc., or its subsidiaries and affiliates. 
 (c) In the event that the Non-Competition Restriction applies to Employee, the Company shall make garden leave payments to Employee for the post-employment portion of the Restricted Period (but for not more than 12 months following the end
of Employee’s employment) at the rate of 50% of the highest annualized base salary paid to Employee by the Company within the two-year period preceding the last day of Employee’s employment (the
“Garden Leave Pay”). Employee acknowledges and agrees that the Garden Leave Pay is consideration mutually agreed upon by the Company and Employee, and in exchange for Employee’s agreement to the Noncompetition Restriction. Employee
further acknowledges and agrees that any Garden Leave Pay he receives pursuant to this Agreement shall reduce (and shall not be in addition to) any severance or separation pay that Employee is otherwise entitled to receive from the Company pursuant
to any agreement, plan or otherwise. 

  
 4 

 (c) Employee acknowledges that this covenant in this Section 5 is necessary because the
Company’s legitimate business interests cannot be adequately protected solely by the other covenants in this Agreement. 
  

	6.	 Returning Company Documents. Employee agrees that, at the time of leaving the Company, Employee
will promptly deliver to the Company (and will not keep on a computer or otherwise in Employee’s possession, recreate or deliver to anyone else) any and all documents, records, data, notes, reports, proposals, lists, correspondence,
specifications, drawings, blueprints, sketches, materials, devices, equipment, other property, or reproductions of any aforementioned items developed by Employee pursuant to Employee’s employment with the Company or otherwise belonging to the
Company, its successors or assigns, including, without limitation, those records maintained pursuant to paragraph 2(d). In the event of the termination of Employee’s employment, Employee agrees to sign and deliver the “Termination
Certification” attached hereto as Exhibit 2. 

  

	7.	 Representations. Employee agrees to execute any proper oath or verify any proper document
required to carry out the terms of this Agreement. Employee represents that Employee’s performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by Employee in confidence
or in trust prior to Employee’s employment by the Company. Employee hereby represents and warrants that Employee has not entered into, and Employee will not enter into, any oral or written agreement in conflict herewith.

  

	8.	 Restrictions on Solicitation. During any period in which Employee renders consulting services to
the Company and for a period of twelve (12) months thereafter, Employee shall not recruit or otherwise solicit, entice, induce or divert, or attempt to solicit, entice, induce or divert, any employees or customers of the Company, or any of its
subsidiaries or affiliates, to terminate their employment with, or otherwise cease their relationships with (as applicable), the Company or any of its subsidiaries or affiliates. 

 

	9.	 Remedies Upon Breach. Employee understands the restrictions in this Agreement are necessary for
the protection of the business and goodwill of the Company and Consultant considers them to be reasonable for such purpose. Any breach of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of
such breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief, without the posting of a bond. If Employee violates this Agreement, in addition to all other
remedies available to the Company at law, in equity, and under contract, Employee agrees that he is obligated to pay all the Company’s costs of enforcement of this Agreement, including reasonable attorneys’ fees and expenses.

  
 5 

	10.	 General Provisions. 

(a) Governing Law; Arbitration. This Agreement will be governed by the laws of the State of Delaware. Employee and the Company
agree to submit to mandatory binding arbitration, in New York, New York, any and all claims arising out of or related to this Agreement, except that each party may, at its or his option, seek injunctive relief in court in accordance with
Section 8 of this Agreement. EMPLOYEE AND THE COMPANY HEREBY WAIVE ANY RIGHTS TO TRIAL BY JURY IN REGARD TO SUCH CLAIMS. The arbitration shall be conducted through JAMS before a single neutral arbitrator, in accordance with the JAMS
employment arbitration rules then in effect. The arbitrator shall issue a written decision that contains the essential findings and conclusions on which the decision is based. 

(b) Entire Agreement. The Amended and Restated Executive Employment Agreement (the “Employment Agreement”) to
which this Agreement is attached, together with Prior Exhibits and the Equity Documents, as amended (both as defined in the Employment Agreement), set forth the entire agreement and understanding between the Company and Employee relating to the
subject matter herein and supersede all prior discussions or representations between us including, but not limited to, any representations made during Employee’s interview(s), whether written or oral. No modification of or amendment to this
Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by the President of the Company and Employee. Any subsequent change or changes in Employee’s duties, or compensation will not affect the
validity or scope of this Agreement. Terms with initial capitalization that are not otherwise defined in this Restrictive Covenants Agreement have the meanings set forth in the Employment Agreement. 

(c) Enforcement. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions
will continue in full force and effect. If any part of this Agreement is for any reason held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it shall then appear. 
 (d) Successors and Assigns. This Agreement
will be binding upon Employee’s heirs, executors, administrators and other legal representatives and will be for the benefit of the Company, its successors, and its assigns. 

(e) Notices. Any notices required or permitted hereunder shall be given to the appropriate party at the party’s last
known address. Such notice shall be deemed given upon personal delivery to the last known address or if sent by certified or registered mail, three days after the date of mailing. 

(f) Survival. The provisions of this Agreement shall survive the termination of Employee’s employment for any reason
and assignment of this Agreement by the Company to any successor in interest or other assignee. 

  
 6 

 (g) Headings. The headings to each section or paragraph of this
Agreement are provided for convenience of reference only and shall have no legal effect in the interpretation of the terms hereof. 

Employee has read this Restrictive Covenants Agreement and understand its terms. Employee has completely filled out Exhibit 1 to this
Agreement relating to Prior Inventions. 
 Employee understands that this agreement affects Employee’s rights to Inventions that
Employee makes during Employee’s employment with the Company, restricts Employee’s rights to disclose or use Proprietary Information and Third Party Information or subsequent to Employee’s period of employment, and prohibits Employee
from competing with the Company and from soliciting Company employees and Business Partners for one year after Employee’s employment is terminated for any reason. 

Employee further understands that by signing below, he certifies that he (i) was provided with this Agreement at least ten
(10) business days before the effective date of the Agreement and (ii) he has been advised by the Company that he has a right to consult with counsel prior to signing this agreement. 

Employee is executing this Agreement voluntarily. 

In witness whereof, the undersigned has executed this Agreement as a sealed instrument that shall become effective upon the later of
(i) the date this Agreement becomes fully executed by the parties or (ii) ten (10) business days after the Company provided Employee with this Agreement. 
  

									
	Employee	 		 	
					
	Signature:	 	 /s/ David Hallal
	 		 	Date:	 	 10/2/2019

	Print Name:	 	David Hallal	 		 		 	
	Address:	 		 		 		 	

 ACCEPTED AND AGREED TO: 

									
	Allovir, Inc.	 		 	
					
	Signature:	 	 /s/ John Wilson
	 		 	Date:	 	 10/2/2019

					
	Print Name:	 	John Wilson	 		 		 	
					
	Title:	 	Director	 		 		 	

  
 7 

 EXHIBIT 1 

LIST OF PRIOR INVENTIONS 

AND ORIGINAL WORKS OF AUTHORSHIP 
  

	☒	 No inventions or improvements 

 

	☐	 Additional Sheets Attached 

 

			
		
	Signature of Employee:	 	 /s/ David Hallal

		
	Print Name of Employee:	 	David Hallal

			
		
	Date:	 	 10/2/2019

  
 8 

 EXHIBIT 2 

TERMINATION CERTIFICATION 
 This is to
certify that Employee does not have on a computer or otherwise in Employee’s possession, nor has Employee failed to return, any documents, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints,
sketches, materials, devices, equipment, or other property, or reproductions of any aforementioned items belonging to Allovir, Inc., its subsidiaries, affiliates, successors or assigns (together, the “Company”). 

Employee further certify that Employee has complied with all the terms of the Company’s Restrictive Covenants Agreement signed by Employee, including the
reporting of any inventions and original works of authorship (as defined therein), conceived or made by Employee (solely or jointly with others) covered by that agreement. 

Employee further agrees that, in compliance with the Restrictive Covenants Agreement, Employee will preserve as confidential all trade secrets, confidential
knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans,
financial information or other subject matter pertaining to any business of the Company or any of its employees, clients, consultants or licensees. 

Employee further agrees that, for the applicable periods and as otherwise set forth in Restrictive Covenants Agreement, Employee will honor the restrictions
on Employee’s activities (directly or indirectly) as set forth therein. 
  

	
	Date:
	
	   

	David Hallal

  
 9 

 EXHIBIT B 

SEPARATION AGREEMENT AND RELEASE 

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]